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Amphotericin B (AmB) in its liposomal form is now considered as either ﬁrst- or second-line treatment
against Leishmania infections in different part of the world. Few cases of AmB resistance have been
reported and resistance mechanisms toward AmB are still poorly understood. This paper reports a
large-scale comparative proteomic study in the context of AmB resistance. Quantitative proteomics using
stable isotope labeling of amino acids in cell culture (SILAC) was used to better characterize cytoplasmic
and membrane-enriched (ME) proteomes of the in vitro generated Leishmania infantum AmB resistant
mutant AmB1000.1. In total, 97 individual proteins were found as differentially expressed between the
mutant and its parental sensitive strain (WT). More than half of these proteins were either metabolic
enzymes or involved in transcription or translation processes. Key energetic pathways such as glycolysis
and TCA cycle were up-regulated in the mutant. Interestingly, many proteins involved in reactive oxygen
species (ROS) scavenging and heat-shock proteins were also up-regulated in the resistant mutant. This
work provides a basis for further investigations to understand the roles of proteins differentially
expressed in relation with AmB resistance.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Protozoan parasites of the genus Leishmania cause a wide range
of diseases affecting 12 million people worldwide with 1.5–2
million new cases each year (Murray et al., 2005). With no vaccine
available yet, the control of these parasites relies solely on chemo-
therapy. The ﬁrst-line of treatment relies on pentavalent antimony
(SbV) compounds (Alvar et al., 2006). However, in certain regions
such as Bihar state in India, resistance to SbV is now widespread
and alternative drugs must be used (Lira et al., 1999; Sundar,
2001; Thakur et al., 2001). Alternative drugs such as paromomycin
(Sundar et al., 2007) and the orally administered miltefosine
(Sundar et al., 1998) are effective and used against Leishmania.
Nowadays, liposomal AmB is considered as the best drug available
against visceral leishmaniasis, the most severe form of the disease
that is fatal if untreated (Bern et al., 2006; Chappuis et al., 2007).However, its high cost limits its widespread use in developing
countries (Olliaro and Sundar, 2009).
Clinical resistance to AmB is rare as shown by the absence of
resistance in strains isolated from HIV-1 patients treated repeat-
edly with AmB (Lachaud et al., 2009) although few unusual cases
have been reported recently in India (Srivastava et al., 2011;
Purkait et al., 2012). The molecular mechanisms of AmB resistance
are not very well understood. In vitro generated AmB resistant
mutants showed that ergosterol in the plasma membrane was
replaced by a precursor, cholesta-5,7,24-trien-3b-ol, which pre-
vents the binding and subsequent uptake of the drug (Mbongo
et al., 1998). The same substitution was observed in clinical resis-
tant strains along with a higher expression level of the ABC trans-
porter MDR1 (ABCB4) and of some enzymes involved in thiol
metabolism (Purkait et al., 2012).
Quantitative proteomics is now emerging as a powerful
approach to study drug resistance in microorganisms. Here, we
used the stable isotope labeling of amino acids in cell culture
(SILAC) methodology to study AmB resistance in Leishmania. The
present paper reports for the ﬁrst time the use of a large-scale
quantitative proteomic study to characterize the proteome of an
in vitro selected AmB resistant Leishmania mutant.
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2.1. Cell culture and SILAC
The Leishmania infantum (MHOM/MA/67/ITMAP-263) wild-type
(WT) strain and the in vitro generated resistant mutant
AmB1000.1, which is resistant to 1000 nM of AmB, were described
previously (Moreira et al., 2011). The resistance phenotype to AmB
was tested after 7 and 63 passages in absence of drug and has been
proven to be highly stable in this mutant. For SILAC experiments,
we ﬁrst did an incorporation assay on WT cells to evaluate the
extent of isotopic incorporation and technical noise. This control
experiment allowed us to conﬁrm that 99% of incorporation in
lysine and arginine amino acids was achieved. Thus, promastigotes
of WT and mutant AmB1000.1 were grown in RPMI-1640 medium
for SILAC (minus L-lysine and L-arginine) (Cambridge Isotope Labo-
ratories) supplemented with 75 lM adenosine (Sigma), 28 mM
HEPES (Sigma), 40 lM biotin (Sigma), 1% penicillin–streptomycin
(Wisent), 5 mg/L hemin (MP Biomedicals), 10 lM biopterin and
10% heat-inactivated dialysed foetal bovine serum (Cambridge
Isotope Laboratories). L. infantum WT light medium (normal
isotopic abundance) was also supplemented with 242.26 mg/L
L-arginine (Sigma) and 50.03 mg/L L-lysine, while 253.68 mg/L
13C6-15N4-L-arginine and 62.21 mg/L 13C6-15N2-L-lysine were added
to the resistant mutant heavy medium. Mutant cells were grown in
the heavy complete medium for at least 7 passages to ensure a
minimum of 99% incorporation of heavy isotopes into proteins,
as previously determined in our control incorporation assay. WT
and mutant cells were counted using a haemocytometer and the
resistant strain was then mixed with WT cells in a 1:1 ratio.
2.2. Sample preparation
The membrane-enriched (ME) fraction was obtained by sonica-
tion, ultracentrifugation and further puriﬁcation by Free ﬂow zone
electrophoresis (ZE-FFE) as described previously (Brotherton et al.,
2012). The cytosolic protein extraction was performed in 2D lysis
buffer as described previously (Brotherton et al., 2010). Proteins
were then quantiﬁed using the 2D Quant kit (GE Healthcare).
2.3. Sodium dodecyl sulfate (SDS)-PAGE (1DE)
Protein samples (30 lg) were mixed with 4 premixed protein
sample buffer (BioRad) and b-mercaptoethanol (5% ﬁnal concen-
tration, Sigma), and heated at 95 C for 5 min. Protein mixtures
were then loaded on Precast Criterion XT Bis–Tris gradient gels
(4–12% polyacrylamide, BioRad) and the SDS–PAGE separation
was performed on a Criterion™ gel electrophoresis cell (BioRad)
using a PowerPac 200 BioRad power supply set at 200 V for
50 min. For staining, gels were ﬁxed in a solution of 50% methanol:
7.5% acetic acid for 1 h then incubated overnight with SYPRO Ruby
Protein Gel stain (BioRad). The destaining step was performed for
30 min in a solution of 15% methanol: 7.5% acetic acid. Gel images
were captured on a PerkinElmer ProExpress Proteomic Imaging
system. Each sample lane from the SDS–PAGE gels was cut in 40
fractions (24 fractions above 50 kDa and 16 fractions below
50 kDa) with disposable blade (MEE-15) mounted on a One
Touch GridCutter (Gel Company Inc.).
2.4. Protein in-gel digestion
Bands of interest were extracted from SDS–PAGE gels, placed in
96-well plates and washed extensively with HPLC water. Tryptic
digestion was performed on a MassPrep liquid handling robot
(Waters) according to the manufacturer’s speciﬁcations and tothe protocol of Shevchenko et al. (1996) with minor modiﬁcations
(Havlis et al., 2003). Brieﬂy, proteins were reduced with 10 mM
DTT and alkylated with 55 mM iodoacetamide. Trypsin digestion
was performed using 126 nM of modiﬁed porcine trypsin
(Sequencing grade, Promega) at 58 C for 1 h. Digestion products
were then extracted using 1% formic acid and 2% acetonitrile fol-
lowed by 1% formic acid and 50% acetonitrile. The recovered pro-
tein extracts were pooled, vacuum centrifuge dried and
resuspended into 10 lL of 0.1% formic acid. Aliquots of 2 (for cyto-
solic fractions) or 5 (for ME fractions) lL were analyzed by mass
spectrometry.
2.5. Mass spectrometry for the ME fraction
SILAC experiments for the ME fraction were performed on a ABI
QSTAR XL QqTOF mass spectrometer equipped with a nanospray II
ion source (ABSciex) coupled to an Agilent 1100 HPLC as previously
described (Brotherton et al., 2013). Five microliters of each protein
sample were injected by the Agilent 1100 autosampler onto a
0.075 mm (internal diameter) self-packed IntegraFrit column
(New Objective) packed with an isopropanol slurry of 5 lm Jupiter
C18 (Phenomenex) stationary phase using a pressure vessel set at
700 psi. The length of the column was 12 cm. Samples were run
using a 75 min gradient from 10–40% solvent B (solvent A: 0.1%
formic acid in water; solvent B: 0.1% formic acid in acetonitrile)
at a ﬂow rate of 250 nL/min. An information-dependent acquisition
(IDA) method was set up with the MS survey range set between
400 amu and 1600 amu (1 s) followed by dependent MS/MS scans
with a mass range set between 100 and 1600 amu (3 s) of the 3
most intense ions with the enhanced all mode activated. Dynamic
exclusion was set for a period of 15 s and a tolerance of 100 ppm.
2.6. Mass spectrometry for the cytosolic fraction
SILAC experiments for the cytosolic protein fraction were per-
formed on a TripleTOF 5600 mass spectrometer equipped with a
nanospray III ion source (ABSciex) coupled to an Agilent 1200
HPLC. Two microliter samples were injected by the Agilent 1200
autosampler onto a 0.075 mm (internal diameter) self-packed
PicoFrit column (New Objective) packed with an isopropanol slurry
of 5 lm Jupiter C18 (Phenomenex) stationary phase using a pres-
sure vessel set at 700 psi. The length of the column was 15 cm.
Samples were run using a 65 min gradient from 5–35% solvent B
(solvent A: 0.1% formic acid in water; solvent B: 0.1% formic acid
in acetonitrile) at a ﬂow rate of 300 nL/min. Data were acquired
using an ion spray voltage of 2.4 kV, curtain gas of 30 psi, nebulizer
gas of 8 psi and an interface heater temperature of 125 C. An infor-
mation-dependent acquisition (IDA) method was set up with the
MS survey range set between 400 amu and 1250 amu (250 ms) fol-
lowed by dependent MS/MS scans with a mass range set between
100 and 1800 amu (50 ms) of the 20 most intense ions in the high
sensitivity mode with a 2+ to 5+ charge state. Dynamic exclusion
was set for a period of 3 s and a tolerance of 100 ppm.
2.7. Interpretation of tandem mass spectra and protein identiﬁcation
Raw data ﬁles (n = 40 for each sample) were submitted for
simultaneous searches using the Protein Pilot version 4 software
(ABSciex) utilizing the Paragon and Progroup algorithms (Shilov
et al., 2007). The Protein Pilot program was set up to search the
L. infantum proteins in the TriTrypDB LeishPEP database (http://
tritrypdb.org/common/downloads/release-4.0/Linfantum/fasta/Lin
fantumAnnotatedProteins_TriTrypDB-4.0.fasta) with carbamidom-
ethyl (C) as a ﬁxed modiﬁcation and standard SILAC (Lys +8, Arg
+10) settings for QSTAR or TripleTof 5600 instruments. Proteins
for which at least two fully trypsin-digested light (L) and heavy
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value lower than 0.05 were used for subsequent comparative
quantitative analysis.3. Results and discussion
Lipid formulations of the polyene antibiotic AmB are now the
mainstay for the treatment of Leishmania in the epidemic region
of Bihar in India where nearly 65% of the cases are refractory to
the ﬁrst line antimonial drugs (Bern et al., 2006; Chappuis et al.,
2007). Although some sporadic unusual cases have been reported
recently (Srivastava et al., 2011; Purkait et al., 2012), clinical resis-
tance has not yet threatened the efﬁcacy of AmB, even when used
through many courses as for treating HIV co-infected patients
(Lachaud et al., 2009). Using a SILAC-based quantitative proteomic
method, we probed proteome alterations induced in an in vitro
selected L. infantum AmB1000.1 resistant mutant. Since membrane
proteins are often underrepresented in proteomic studies, we
choose to analyze SILAC-labeled membrane enriched (ME) and
cytosolic proteins separately in order to increase the proteome
coverage.
The L. infantum AmB1000.1 resistant mutant was grown in the
presence of 13C6-15N4-L-arginine and 13C6-15N2-L-lysine while the
parental L. infantum WT strain was maintained in the same med-
ium containing normal isotopic abundance amino acids. Both cell
populations were counted and mutant parasites were mixed with
WT cells in a 1:1 ratio. ME and cytosolic fractions were extracted
from the mixed population and both fractions were independently
subjected to SDS–PAGE separation. Each sample line was further
fractionated into 40 pieces of gel, proteins were gel extracted, tryp-
sin digested and peptides were identiﬁed and quantiﬁed by mass
spectrometry and isotopic quantiﬁcation. Only protein identiﬁca-
tions with differences in their expression level greater than
1.2-fold when comparing mutant and WT levels were considered
as signiﬁcant. This expression threshold was selected after having
performed a control experiment to evaluate the extent of isotopic
incorporation and technical noise. A fold change of 1.2 was consid-
ered as an expression threshold well above background. Thus, 99
protein identiﬁcations corresponding to 97 individual proteins
were assigned as differentially expressed in the AmB1000.1
mutant (Table 1). Among them, 83 (84%) were up-regulated and
16 (16%) were down-regulated. Two proteins (LinJ.03.0190 and
LinJ.24.1700) were identiﬁed independently in both ME and cyto-
solic fractions as indicated in Table 1. With only two exceptions
(LinJ.23.0880 and LinJ.32.0280), all the cytosolic proteins identiﬁed
in this study were predicted to be devoid of transmembrane
domains (TMDs) according to the TMHMM v2.0 algorithm
(Table 1). In contrast, a quarter (23%) of the proteins differentially
expressed in ME fraction were predicted to have at least one TMD.
The identiﬁcation of proteins with no predicted TMD inME fraction
might be possibly explained by non-covalent interactions with
components of membranes through hydrogen bonding, van der
Waals contacts or electrostatic attractions. These types of interac-
tions are known to play critical roles in maintaining cell membrane
structure and facilitating membrane functions (reviewed in Prinz
and Hinshaw, 2009).
Differentially expressed proteins with statistical signiﬁcance
were sorted into functional classes according to GeneDB annota-
tions and Gene Ontology. Metabolism (27%) and transcription/
translation (26%) were the main functional classes represented in
this study corresponding together to more than half of all the iden-
tiﬁed proteins (Fig. 1). Another quarter of the protein hits were
represented by hypothetical proteins (13%) or involved in protein
folding (12%) (Fig. 1). Other functional groups, each of which rep-
resenting less than 5% of the identiﬁcations, were proteolysis,transport, cytoskeleton and surface proteins, whereas 9% of the
identiﬁed proteins were not assigned to any of the aforementioned
classes (Fig.1).
Three enzymes playing a role in the conversion of S-adenosyl-L-
homocysteine to S-adenosyl-L-methionine, namely the S-adenosyl-
homocysteine hydrolase (LinJ.36.4100), cobalamin-dependant
methionine synthase (LinJ.07.0240) and S-adenosylmethionine
synthetase (LinJ.30.3580), were up-regulated in the AmB resistant
mutant (Table 1). Since S-adenosyl-L-methionine is involved in
many cellular functions, including stress response, it may explain
why this pathway was increased in the AmB mutant. Other key
metabolic pathways detected in AmB1000.1 resistant mutant as
being up-regulated included glycolysis with the hexokinase
(LinJ.21.0310), fructose-1,6-bisphosphate aldolase (LinJ.36.1320),
glyceraldehyde 3-phosphate dehydrogenase (LinJ.30.3000) and
enolase (LinJ.14.1240) as well as the TCA cycle with the aconitase
(LinJ.18.0510), GCVL-2 dihydrolipoamide dehydrogenase
(LinJ.32.3510) and malate dehydrogenase (LinJ.34.0150) (Table 1).
Curiously, the succinate dehydrogenase ﬂavoprotein (LinJ.24.1700),
another enzyme involved in the TCA cycle, was found to be up-reg-
ulated in the cytosolic protein fraction (1.98-fold) but down-regu-
lated in the ME fraction (1.90-fold). The reason for this discrepancy
is unknown. The modulation of several glycolytic enzymes in an
AmB resistance context is mimicking the glycolysis state level pre-
viously reported in L. donovani antimony in vitro resistant cell lines
(Biyani et al., 2011) and may thus corresponds to a general stress
response more than a speciﬁc drug response. However, the TCA
cycle enzymes aconitase and malate dehydrogenase as well as
the inositol phosphate metabolism enzyme myo-inositol-1-phos-
phate synthase were also found to be up-regulated in response
to AmB in a previous Candida albicans proteomic study
(Hoehamer et al., 2010), similarly as we observed here and thus
might be involved in the AmB resistance phenotype acquired from
our in vitro Leishmania mutant.
A number of enzymes part of the reactive oxygen species (ROS)
induced pathway was overproduced in our AmB mutant namely
the trypanothione reductase (TR) (LinJ.05.0350) as well as two dif-
ferent tryparedoxin peroxidases (TPX) (LinJ.15.1100 and
LinJ.23.0050) (Table 1). In addition to the tryparedoxin cascade
which was previously shown to be up-regulated in AmB clinical
unresponsive strain (Purkait et al., 2012), increased reduced thiols
by an overproduction of TR in the AmB resistant parasites may also
be involved in better antioxidant defense as it was already
reported in the case of antimony resistance (Wyllie et al., 2008).
Nonetheless, transfection of these individual genes (encoding TR
and TXP) did not lead to a resistance phenotype to AmB
(Table S1) suggesting that if they are involved in resistance it must
be a more subtle role. AmB has been proposed to kill Aspergillus
terreus by inducing intracellular oxidation leading to lipid peroxi-
dation and ultimately cell death (Blum et al., 2013a). Thus, TR
and TXP might possibly act by interfering somehow with this cell
death pathway. It is also interesting to note that the detoxifying
enzyme SODB2 iron superoxide dismutase (LinJ.32.1920) was sim-
ilarly overproduced in the AmB mutant. This enzyme is known in
several other organisms to be modulated in response to oxidative
stress (Alscher et al., 2002). Moreover, superoxide dismutase was
also shown to protect C. albicans from oxidative damage caused
by AmB (Sokol-Anderson et al., 1986). However, transfection of
SODB2 failed to show a direct role for resistance to AmB
(Table S1) and further work would be required.
Many proteins involved in protein folding, such as heat-shock
proteins and chaperonins, were also found to be up-regulated in
AmB1000.1 suggesting a putative role of these proteins in AmB
resistance or tolerance. In particular, the heat shock protein 83-1
(Hsp83-1, LinJ.33.0370) was found up-regulated in the AmB
resistant mutant compared to WT cells (Table 1). This protein is
Table 1
MS/MS identiﬁcations of differentially expressed proteins in AmB1000.1 compared to WT in SILAC experiments.
Systematic
IDs
Putative protein name Unique peptidesa
(% sequence
coverage)
Ratio AmB
1000.1/WT
p-value Error
factor
TMDsb Fractionc
Transport
LinJ.18.1510 H1A-2 P-type H+-ATPase, putative 15 (14.48) 2,51 0,0130 2,02 8 M
LinJ.25.1210 ATPase beta subunit, putative 18 (31.62) 1,68 0,0009 1,29 0 C
LinJ.30.3660 ATP synthase, epsilon chain, putative 2 (16.57) 2,25 0,0892 4,28 0 C
Surface
LinJ.10.0500 GP63, leishmanolysin,metallo-peptidase,
Clan MA(M), Family M8
24 (27.38) 4,14 0,0001 1,83 1 M
LinJ.30.0930 Amastin-like surface protein-like protein 2 (4.05) 2,61 0,0897 5,65 4 M
Cytoskeleton
LinJ.19.0680 Kinesin, putative 9 (8.70) 1,98 0,0001 1,25 0 C
LinJ.23.0720 Kinesin, putative 5 (6.86) 1,78 0,0167 1,50 0 M
LinJ.30.0350 Kinesin, putative 4 (6.39) 2,18 0,0316 1,84 0 C
Metabolism
LinJ.03.0190 Delta-1-pyrroline-5-carboxylate dehydrogenase, putative 8 (13.39) 1,26 0,0417 1,25 0 M
LinJ.03.0190 Delta-1-pyrroline-5-carboxylate dehydrogenase, putative 10 (21.43) 1,67 0,0045 1,37 0 C
LinJ.05.0350 Trypanothione reductase 2 (5.50) 2,50 0,0320 2,06 0 C
LinJ.07.0240 Cobalamin-dependant methionine synthase, putative 3 (2.24) 1,91 0,0334 1,74 0 C
LinJ.14.0680 Fatty acid elongase, putative 2 (5.63) 2,22 0,0936 4,47 6 M
LinJ.14.1240 Enolase 9 (24.48) 1,53 0,0706 1,60 0 C
LinJ.14.1450 Myo-inositol-1-phosphate synthase 2 (4.56) 1,91 0,0975 3,57 0 C
LinJ.15.1100 Tryparedoxin peroxidase 10 (32.16) 1,81 0,0548 1,86 0 C
LinJ.18.0510 Aconitase, putative 26 (33.15) 1,37 0,0687 1,41 0 C
LinJ.21.0310 Hexokinase, putative 14 (31.42) 1,85 0,0036 1,42 0 C
LinJ.21.1490 Adenylate kinase, putative 2 (9.29) 3,23 0,0546 3,55 0 C
LinJ.22.0190 Carnitine palmitoyltransferase-like protein 1 (2.22) 4,34 0,0560 5,19 0 M
LinJ.23.0050 Peroxidoxin, tryparedoxin peroxidase 2 (8.41) 2,67 0,0276 2,18 0 C
LinJ.23.0860 ERG10 3-ketoacyl-coa thiolase-like protein 2 (7.26) 2,47 0,0140 1,59 0 C
LinJ.23.0880 Acetyl-CoA synthetase, putative 5 (7.63) 2,17 0,0054 1,53 1 C
LinJ.24.1700 Succinate dehydrogenase ﬂavoprotein, putative 6 (12.03) 1,90 0,0147 1,49 0 M
LinJ.24.1700 Succinate dehydrogenase ﬂavoprotein, putative 5 (9.56) 1,98 0,0127 1,59 0 C
LinJ.30.2920 Aldehyde dehydrogenase, putative 2 (3.59) 1,67 0,0013 1,20 0 M
LinJ.30.3000 Glyceraldehyde 3-phosphate dehydrogenase, glycosomal 18 (41.83) 1,60 0,0048 1,35 0 C
LinJ.30.3580 S-adenosylmethionine synthetase 5 (13.52) 2,22 0,0780 2,53 0 C
LinJ.32.1920 SODB2 iron superoxide dismutase, putative 4 (11.54) 2,41 0,0959 5,46 0 C
LinJ.32.3110 Nucleoside diphosphate kinase b 2 (13.91) 1,60 0,0462 1,58 0 M
LinJ.32.3510 GCVL-2 dihydrolipoamide dehydrogenase, putative 8 (17.44) 1,62 0,0086 1,40 0 C
LinJ.34.0150 Malate dehydrogenase 5 (18.30) 1,55 0,0526 1,56 0 C
LinJ.35.1190 NADH-dependent fumarate reductase, putative 25 (23.98) 1,40 0,0033 1,23 0 C
LinJ.36.1320 Fructose-1,6-bisphosphate aldolase 10 (23.99) 1,64 0,0073 1,38 0 C
LinJ.36.4100 S-adenosylhomocysteine hydrolase 12 (25.63) 1,54 0,0547 1,55 0 C
Protein folding
LinJ.21.1330 T-complex protein 1, delta subunit, putative 11 (15.79) 1,86 0,0229 1,67 0 C
LinJ.23.1460 T-complex protein 1, gamma subunit, putative 10 (18.51) 1,58 0,0161 1,39 0 C
LinJ.26.1360 Prefoldin-like protein 5 (27.84) 1,62 0,0522 1,63 0 C
LinJ.28.3060 Heat-shock protein hsp70, putative 45 (38.59) 1,55 0,0004 1,24 0 C
LinJ.30.2540 Heat shock 70-related protein 1, mitochondrial precursor, putative 42 (46.82) 1,93 0,0097 1,63 0 C
LinJ.32.1060 Chaperonin containing t-complex protein, putative 7 (11.71) 1,95 0,0053 1,47 0 C
LinJ.32.1940 Chaperonin Hsp60, mitochondrial precursor, putative 3 (5.05) 2,40 0,0123 1,53 0 C
LinJ.32.3470 Chaperonin alpha subunit, putative 20 (36.63) 1,72 0,0004 1,29 0 C
LinJ.33.0370 Heat shock protein 83-1 28 (26.86) 1,52 0,0042 1,31 0 C
LinJ.33.2520 Heat shock protein, putative 16 (17.98) 1,52 0,0172 1,39 0 C
LinJ.36.2140 Chaperonin Hsp60, mitochondrial precursor 44 (54.98) 2,14 4,611E-06 1,21 0 C
LinJ.36.7240 Chaperonin, putative,T-complex protein 1 (theta subunit), putative 13 (24.77) 1,93 1,289E-05 1,22 0 C
Proteolysis
LinJ.09.0820 Oligopeptidase b,serine peptidase, clan SC, family S9A-like protein 4 (6.02) 1,56 0,0870 1,72 0 C
LinJ.11.0640 Aminopeptidase, putative,metallo-peptidase, Clan MF, Family M17 7 (14.77) 1,45 0,0687 1,50 0 C
LinJ.20.1220 Calpain-like cysteine peptidase, putative,cysteine peptidase, Clan CA,
family C2, putative
3 (4.38) 1,69 0,0115 1,35 0 C
LinJ.36.1730 Proteasome beta 5 subunit, putative 3 (11.92) 1,86 0,0438 1,78 0 C
Transcription, Translation
LinJ.01.0800 Eukaryotic initiation factor 4a, putative 10 (26.05) 1,74 0,0468 1,72 0 C
LinJ.06.0410 60S ribosomal protein L19, putative 5 (15.92) 1,21 0,0238 1,17 0 M
LinJ.09.1130 Eukaryotic translation initiation factor 2 subunit, putative 2 (3.34) 2,02 0,0191 1,70 0 C
LinJ.11.0100 Seryl-tRNA synthetase, putative 3 (3.80) 2,17 0,0064 1,55 0 C
LinJ.13.0460 40S ribosomal protein S12, putative 8 (29.79) 1,93 0,0001 1,20 0 C
LinJ.17.0110 Elongation factor 1-alpha 23 (38.37) 1,65 0,0014 1,32 0 C
LinJ.18.0740 Elongation factor Tu, putative 2 (5.59) 1,82 0,0530 1,85 0 C
LinJ.21.0600 la RNA binding protein, putative 5 (20.54) 1,50 0,0409 1,46 0 C
LinJ.21.1310 40S ribosomal protein S23, putative 4 (18.88) 1,32 0,0324 1,26 0 M
(continued on next page)
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Fig. 1. Functional assignment of proteins found differentially expressed by SILAC
between L. infantum WT and AmB1000.1 mutant. Protein functional classiﬁcation
was based on GeneDB annotations and Gene Ontology.
Table 1 (continued)
Systematic
IDs
Putative protein name Unique peptidesa
(% sequence
coverage)
Ratio AmB
1000.1/WT
p-value Error
factor
TMDsb Fractionc
LinJ.25.0760 Eukaryotic initiation factor 5a, putative 2 (8.17) 2,27 0,0497 2,27 0 C
LinJ.26.2360 60S ribosomal protein L35, putative 4 (14.17) 1,30 0,0374 1,26 0 M
LinJ.27.2480 60S acidic ribosomal subunit protein 3 (9.91) 2,17 0,0166 1,55 0 C
LinJ.29.1920 40S ribosomal protein S15A, putative 3 (20.77) 2,00 0,0659 2,18 0 C
LinJ.30.3650 40S ribosomal protein S14 4 (20.14) 1,43 0,0057 1,20 0 C
LinJ.32.0410 ATP-dependent RNA helicase, putative 17 (27.52) 1,56 0,0050 1,33 0 C
LinJ.32.2850 Ribosomal protein L27, putative 6 (28.36) 1,23 0,0630 1,24 0 M
LinJ.35.0240 60S ribosomal protein L30 7 (56.73) 1,92 0,0236 1,70 0 C
LinJ.35.1880 60S ribosomal protein L5, putative 5 (11.48) 1,28 0,0194 1,20 0 M
LinJ.35.2000 40S ribosomal protein S6, putative 3 (4.02) 1,22 0,0727 1,26 0 M
LinJ.35.3840 60S ribosomal protein L23, putative 3 (25.90) 2,19 0,0433 2,07 0 C
LinJ.35.5360 Polyadenylate-binding protein 1, putative 6 (9.11) 1,77 0,0190 1,55 0 C
LinJ.36.0020 Histone H4 5 (26.00) 1,31 0,0043 1,17 0 M
LinJ.36.3950 RPL10a 60S ribosomal protein L10a, putative 6 (15.42) 1,31 0,0863 1,39 0 M
LinJ.36.4730 RPL18 60S ribosomal protein L18, putative 3 (13.13) 1,56 0,0409 1,49 0 M
LinJ.36.5870 Isoleucyl-tRNA synthetase, putative 5 (4.18) 1,96 0,0566 2,03 0 C
LinJ.36.7320 Eukaryotic translation initiation factor 3 subunit 8, putative 7 (6.16) 1,39 0,0698 1,44 0 M
Others
LinJ.14.0990 Immunodominant antigen, putative,tc40 antigen-like 5 (6.97) 1,48 0,0707 1,54 0 C
LinJ.16.1710 Prohibitin, putative 4 (16.42) 1,28 0,0695 1,32 0 M
LinJ.20.0820 Vesicle-fusing ATPase, putative,N-ethylmaleimide-sensitive factor,
putative
5 (7.86) 1,55 0,0832 1,68 0 C
LinJ.23.0120 GDP-mannose pyrophosphorylase 3 (9.50) 1,88 0,0683 2,06 0 C
LinJ.28.2430 Glycosomal membrane protein, putative 4 (10.36) 1,66 0,0016 1,20 0 M
LinJ.34.0720 Flagellar attachment zone protein 4 (10.92) 1,88 0,0676 2,02 0 C
LinJ.34.2680 Regulatory subunit of protein kinase a-like protein 9 (12.52) 1,83 0,0002 1,21 0 C
LinJ.35.0070 Prohibitin, putative 2 (6.16) 1,71 0,0182 1,43 1 M
LinJ.36.3360 14-3-3 protein-like protein 2 (8.53) 1,98 0,0144 1,43 0 C
Hypothetical
LinJ.08.1010 Hypothetical protein, conserved 3 (8.77) 1,89 0,0563 1,94 0 C
LinJ.09.0120 Hypothetical protein, conserved,calmodulin-like protein containing EF
hand domain
6 (13.75) 1,40 0,0382 1,36 0 C
LinJ.09.1070 Hypothetical protein, conserved 8 (15.93) 1,53 0,0699 1,60 0 C
LinJ.09.1530 Hypothetical protein, conserved 2 (13.74) 2,15 0,0395 1,96 0 C
LinJ.13.0740 Hypothetical protein, conserved 8 (9.88) 2,13 0,0222 1,82 0 C
LinJ.16.1050 Hypothetical protein, conserved 3 (4.91) 1,77 0,0802 1,97 0 M
LinJ.17.0780 Hypothetical protein, conserved 4 (5.21) 1,72 0,0840 2,06 0 C
LinJ.23.0810 Hypothetical protein, conserved 3 (3.96) 1,52 0,0010 1,22 4 M
LinJ.25.2100 Hypothetical protein, conserved 2 (7.87) 1,60 0,0235 1,44 0 C
LinJ.27.1220 Hypothetical protein, conserved 6 (9.64) 1,65 0,0431 1,61 0 C
LinJ.29.1570 Hypothetical protein, conserved 2 (3.23) 2,40 0,0717 3,51 0 C
LinJ.32.0280 Hypothetical protein, conserved 5 (4.07) 1,59 0,0650 1,68 2 C
LinJ.36.5380 Hypothetical protein, conserved; kinesin-like protein, putative 7 (10.88) 1,51 0,0108 1,33 0 M
a Peptide identiﬁcations were accepted if they reached greater than 95% probability as speciﬁed by the Peptide Prophet algorithm.
b TMDs were predicted using TMHMM v2.0.
c M, membrane-enriched fraction; C, cytosolic fraction.
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be a key player in AmB resistance in A. terreus (Blum et al.,
2013b). Furthermore, Hsp60, some Hsp70 and S-adenosylmethio-
nine synthetase were also found to be up-regulated in C. albicans
in response to AmB through a proteomic screen (Hoehamer et al.,
2010). The role of heat shock proteins in resistance in Leishmania
has not been directly assessed by gene transfection however
(Table S1).
AmB is known to bind to the membrane ergosterol of sensitive
Leishmania strains, causing pore formation in the membrane and
leakage of ions like K+ which results ultimately in cell death
(Cohen et al., 1986; Saha et al., 1986). The H1A-2 P-type H+-ATPase
(LinJ.18.1510) was down-regulated in our AmB mutant. Pma1p, the
orthologous protein in yeast, is involved in the regulation of intra-
cellular pH by hydrogen efﬂux (reviewed in Morsomme et al.,
2000). We may therefore hypothesize that the down-regulation
of this proton pump at the parasite cell surface might prevent H+
M.-C. Brotherton et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 126–132 131expulsion and thus might help maintaining the membrane poten-
tial gradient necessary to survive K+ leaking. Overexpression
experiments did not lead to a phenotype, however (Table S1), so
the gene product encoded by LinJ.18.1510 cannot be considered
per se as an AmB resistance gene but still can be a contributing fac-
tor to the high level of AmB resistance since its proton activity
might be a futile waste of ATP in the presence of pores in the mem-
brane, thus unnecessarily depleting the parasite of ATP. Further
experiments such as inactivation of the gene are required to assess
any role of this candidate in AmB resistance in Leishmania.
Overall, the genes coding for 18 candidate proteins being
detected either as up- or down-regulated from our quantitative
proteomic analysis were cloned in an episomal vector and trans-
fected in L. infantum WT and AmB resistant mutant cells, respec-
tively (Table S1). These genes were selected because literature
data were indicating a potential role in drug resistance in other
organisms or because some motifs of these proteins were suggest-
ing a possible link with chemoresistance or drug tolerance. Trans-
fection experiments failed to show any direct link with AmB
resistance, however. Since multiple mutations can co-exist and
lead to drug resistance in Leishmania (Coelho et al., 2012; Ritt
et al., 2013), it remains to be tested if a combination of two or more
genes may lead to AmB resistance when co-transfected in the same
recipient cell. A large number of protein candidates (n = 97) differ-
entially expressed in our mutant were discovered and some might
be only related to a stress response and not to the drug itself. One
possible approach to decrease the false-negative discovery rate in
SILAC proteomic experiments would be to study more than one
mutant and concentrate on recurrent mutations in independent
mutants. This strategy has indeed improved the quality of our
dataset in other large genomic scale studies (Coelho et al., 2012;
Ritt et al., 2013).
In conclusion, this large-scale proteomic study of an in vitro
AmB Leishmania resistant mutant allowed the identiﬁcation of 97
individual differentially expressed proteins when compared to
the parental sensitive strain. While the candidate proteins tested
by transfection were not directly involved in AmB resistance, sev-
eral of the proteins identiﬁed were observed independently either
in Leishmania or fungus. It is thus possible that some of these puta-
tive candidates may form protein complexes in order to sustain
resistance or that their involvement in resistance is more indirect.
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